Added to YB: 2026-09-09
Pitch date: 2026-09-04
ACHV [bearish]
Achieve Life Sciences, Inc.
+5.77%
current return
Author Info
Shortfinder specializes in in uncovering small-cap companies at risk of dilution, regulatory setbacks, or fundamental weaknesses. Sign up for the newsletter.
Company Info
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
Market Cap
$873.6M
Pitch Price
$8.32
Price Target
6.25 (-20%)
Dividend
N/A
EV/EBITDA
-12.10
P/E
-4.69
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Shortfinder Research: Achieve Life Sciences (ACHV): Approval Is the Exit
ACHV (short): Achieve Life Sciences is a dilution short rather than a bet against cytisinicline: short at $8.31 with a $6.25 target and $9.65 stop through the Q4 NDA resubmission. Some 69.9M in-the-money warrants could lift shares outstanding 68% and expire shortly after approval, while a new $150M ATM sits atop $187.3M of cash. Likely approval, crowded short interest and acquisition risk warrant a half-sized position.
Read full article (8 min)